Mark Sulkowski, MD

CRS:

JHU

Role:

Investigators

Position:

Site Investigator

Email:

msulkows@jhmi.edu
  • Chair, Hepatitis TSG (Dec 2016)
  • Chair, Steering Committee of Hepatitis TSG (Dec 2016)
  • SC Representative, Scientific Agenda Steering Committee (Dec 2014)
  • Member, HBV Cure Working Group of the HEP TSG (Mar 2015)
  • Co-Chair, NASH Focus Group of the ITSG/HEPTSG (April 2016)
  • Chair 5329
  • Vice-Chair, 5360
  • Co-chair 5334s
  • Investigator, 5335s

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More